Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of SYH2059 Powder for Inhalation in Healthy Participants
NCT07510958Phase 1Not yet recruiting
- Sponsor
- InnovStone Therapeutics
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of SYH2059 (4 arms), sponsored by InnovStone Therapeutics. Primary endpoint: Number of adverse events at 72 hours. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SYH2059
Beyond the preview
Go deeper on NCT07510958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07510958.